Bromfenac 0.09% for the treatment of macular edema secondary to noninfectious uveitis

Simple item page
dc.contributor.authorS.Saade, Joanna S.
dc.contributor.authorIstambouli, Rachid
dc.contributor.authorAbdulaal, Marwan R.
dc.contributor.authorAntonios, Rafic S.
dc.contributor.authorHamam, Rola N.
dc.contributor.departmentOphthalmology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:08:50Z
dc.date.available2025-01-24T12:08:50Z
dc.date.issued2021
dc.description.abstractPURPOSE: The topical nonsteroidal anti-inflammatory drug bromfenac 0.09% has a potential benefit in uveitic macular edema (UME) with a safe side effect profile. The aim of the study is to assess the efficacy of bromfenac sodium solution in the treatment of UME. METHODS: The charts of 10 patients with macular edema due to noninfectious uveitis treated with bromfenac 0.09% were reviewed retrospectively. The main outcomes studied were the best-corrected visual acuity (BCVA) and the central retinal thickness (CRT) compared 4 months before bromfenac initiation, at the time of its initiation, and 4 months later. RESULTS: Twelve eyes of 10 patients were included. BCVA and CRT were unchanged 4 months befoew bromfenac compared to the time of bromfenac initiation (P = 1.0 and P = 0.2, respectively). There were a significant improvement in BCVA after 4 months of bromfenac treatment (P = 0.043) and a significant decrease in CRT (P = 0.002). Subretinal fluid resolved completely in 8/9 eyes, and 4/9 eyes had a complete resolution of cystoid macular edema at 4 months. CONCLUSION: Bromfenac may be a useful addition to the treatment of UME. © 2021 Middle East African Journal of Ophthalmology | Published by Wolters Kluwer - Medknow.
dc.identifier.doihttps://doi.org/10.4103/meajo.meajo_134_21
dc.identifier.eid2-s2.0-85116408916
dc.identifier.pmid34759667
dc.identifier.urihttp://hdl.handle.net/10938/31931
dc.language.isoen
dc.publisherWolters Kluwer Medknow Publications
dc.relation.ispartofMiddle East African Journal of Ophthalmology
dc.sourceScopus
dc.subjectBromfenac
dc.subjectMacular edema
dc.subjectNonsteroidal anti-inflammatory drugs
dc.subjectOcular inflammation
dc.subjectUveitis
dc.subjectBenzophenones
dc.subjectBromobenzenes
dc.subjectHumans
dc.subjectRetrospective studies
dc.subjectTomography, optical coherence
dc.subjectVisual acuity
dc.subjectAcetazolamide
dc.subjectIndometacin
dc.subjectInfliximab
dc.subjectKetorolac
dc.subjectBenzophenone derivative
dc.subjectBromobenzene
dc.subjectAdult
dc.subjectArticle
dc.subjectBest corrected visual acuity
dc.subjectCase report
dc.subjectCentral retinal thickness
dc.subjectClinical article
dc.subjectCohort analysis
dc.subjectContinuous infusion
dc.subjectControlled study
dc.subjectDrug efficacy
dc.subjectFemale
dc.subjectHuman
dc.subjectMacular thickness
dc.subjectMale
dc.subjectMedical record review
dc.subjectMiddle aged
dc.subjectOptical coherence tomography
dc.subjectRetina macula cystoid edema
dc.subjectRetrospective study
dc.subjectSpondylarthritis
dc.subjectSubretinal fluid
dc.subjectTreatment duration
dc.subjectTreatment indication
dc.subjectTreatment outcome
dc.subjectComplication
dc.titleBromfenac 0.09% for the treatment of macular edema secondary to noninfectious uveitis
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2021-2695.pdf
Size:
894.23 KB
Format:
Adobe Portable Document Format
Download

Collections

Ophthalmology